- +91 8471002000
- Messenger
Immunotherapy
Pembrolizumab
Pembrolizumab Injection
Injection
Brand name: Keytruda Manufacturer: Merck & Co., Inc.
Dosage of Pembrolizumab: 200mg IV infusion, administered triweekly
Pembrolizumab is a revolutionary medication authorized for use against multiple cancer forms, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin's lymphoma, urothelial carcinoma, and gastric and esophageal malignancies. Notably, it shows potency against tumors exhibiting microsatellite instability or defective mismatch repair. This cutting-edge therapy enhances the body's immune response, enabling it to proficiently fight and eradicate cancerous cells.
Pembrolizumab is a revolutionary immunotherapy agent that empowers patients' immune systems to detect and destroy cancerous cells. Ingeniously targeting the PD-1 protein pathway, it thwarts the cancer's tenacious attempts to elude immunity, amplifying the body's natural defenses. With its versatile applicability across diverse cancer types, pembrolizumab signifies a novel era in personalized cancer care strategies.
Pembrolizumab resistance arises from changes in the cancer cells' composition, impeding immune checkpoint disruption and restricting T-cell interaction. As a result, the visibility of cancer antigens diminishes, and suppressive elements intensify. This impairs pembrolizumab's potency, reducing its capacity to effectively counteract tumor advancement.
Utilizing Pembrolizumab injection may result in various unexpected consequences, such as lasting fatigue, ongoing cough, sensations of queasiness, and aggravated skin conditions. In some instances, this therapy might provoke critical incidents, like assaults on an individual's own organs, lung inflammation, hepatic distress, or severe injection-associated complications. Consistent observation is vital for prompt detection and management of these possible risks.
As a potent cancer-fighting agent, Pembrolizumab can be effectively merged with various drugs depending on the specific cancer diagnosis. For instance, in non-squamous NSCLC situations, it is commonly paired with pemetrexed and platinum-derived chemotherapeutic agents such as cisplatin or carboplatin. Moreover, the FDA sanctions the concurrent administration of pembrolizumab and axitinib to combat advanced RCC. Engaging with a medical expert is vital for formulating a fitting therapeutic plan.
Avg cost of Pembrolizumab Injection: ₹62,500 in India. The above price is specific for Ilkal, Karnataka, India
WhatsApp us